Instrument NameEli Lilly and CompanyInstrument Symbol(LLY-N)

Instrument ExchangeNYSE

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.

If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.

Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential

Conditions are getting a bit more challenging for the drugmaker.

The good times aren't over, but the peak of the party might be passing.

Viking stock has slipped more than 20% from its peak.

Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts

We're also talking about Super Micro, Nvidia, and weight loss.

Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users.

The market's perception of the pharmaceutical company has undeniably shifted.

The company's latest presentation supports the idea that its lead program will make billions.

Eli Lilly stock has fallen in the days following the release of its latest earnings numbers.

The company expects to enjoy many GLP-1 tailwinds in 2025.

Eli Lilly's price pullback is an opportunity worth 25%, with analysts' sentiment firming around the $1000 level. New highs are likely by early 2025.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

Size means little in light of this company's prospects.

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly.

The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut.

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

December S&P 500 E-Mini futures (ESZ24) are down -0.77%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -1.09% this morning as investors digested quarterly earnings reports from Microsoft and Meta as well as robust U.S. economic data that muddied the outlook for Federal Reserve rate cuts.

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.79%. Stocks Wednesday relinquished early gains and posted moderate losses as a slide in chip...

LLY earnings call for the period ending September 30, 2024.